NexStar Pharm(NXTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steven Yang who wrote (299)	8/19/1998 10:44:00 PM
From: Miljenko Zuanic	Read Replies (1) of 328

Steven: >>What is your take on today's news about the breakup of NXTR into two separate companies? << Actually, three entity (Proligo). In my projection NXTR-R&D is worth ~100-120 mm (Proligo-oligo, SELEX-diagnostic and target validation, small molecules derived from paralel-SELEX). ZERO (0) value for SELEX-drug. Go Larry, Go! Wish I know where!!!! ~75 mm in cash, 42 mm in account receivable , 60 mm debenture (conversion at ~16.5. My speculation is that NXTR-G will be for sale. All in all, this is good news. Miljenko PS: Well, Pat, it finally happen. Almost I feel sorry for You! :(

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next